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promise to be both effective and exert weaker selection for resistance than conventional 23 antibiotics. However, the evolutionary robustness argument, based on the idea that anti-24 virulence treatments disarm rather than kill pathogens, is controversial. Here we probe the 25 evolutionary robustness of two repurposed drugs, gallium and flucytosine, targeting the iron-26 scavenging pyoverdine of the opportunistic human pathogen Pseudomonas aeruginosa.
27
Methodology: 28 We subjected replicated cultures of bacteria to two concentrations of each drug for 20 29 consecutive days in human serum as an ex-vivo infection model. We screened evolved 30 populations and clones for resistance phenotypes, including the restoration of growth and 31 pyoverdine production, and the evolution of iron uptake by-passing mechanisms. We whole-32 genome sequenced evolved clones to identify the genetic basis of resistance.
33
Results: 34 We found that mutants resistant against anti-virulence treatments readily arose, but their 35 selective spreading varied between treatments. Flucytosine resistance quickly spread in all 36 populations due to disruptive mutations in upp, a gene encoding an enzyme required for 37 flucytosine activation. Conversely, resistance against gallium arose only sporadically, and 38 was based on mutations in transcriptional regulators, upregulating pyocyanin production, a 39 redox-active molecule promoting siderophore-independent iron acquisition. The spread of 40 gallium resistance could be hampered because pyocyanin-mediated iron delivery benefits 41 resistant and susceptible cells alike.
4 aeruginosa [19, 23, 24] . Pyoverdine is an important virulence factor during acute infections 74 [19, [25] [26] [27] [28] [29] [30] [31] . It is required to obtain iron from host proteins, such as transferrin and lactoferrin 75 [32]. Given its importance, it has been proposed that drugs interfering with iron uptake could 76 be effective therapeutics to control infections [33] . Gallium and flucytosine both fulfill this role, 77 albeit through different modes of action. Gallium, a repurposed cancer drug, is an iron-mimic 78 and binds irreversibly to secreted pyoverdine, thereby rendering the molecules useless for 79 iron uptake [19, 23, 31] . Flucytosine, a repurposed anti-fungal drug, enters the bacterium, 80 where it is enzymatically activated to a fluorinated ribonucleotide. This active form inhibits, 81 via a yet unknown mechanism, the expression of the pvdS iron starvation sigma factor 82 controlling pyoverdine synthesis [24, 34] . 83 
84
In a first set of experiments, we examined whether these two drugs affect the growth of P. active enzymes [38, 39] . Flucytosine, once activated, is known to affect RNA synthesis, 91 which might negatively affect growth [40] . 92 
93
In a second experiment, we examined whether mutants, resistant against these two 94 repurposed drugs, evolve and spread through bacterial populations. To this end, we exposed including the restoration of growth, restoration of virulence factor production, and the 101 evolution of a bypassing mechanism for iron uptake [15, 19] 
Results

227
Gallium and flucytosine curb growth and pyoverdine production in human 228 serum.
229
To confirm that human serum is an iron-limited media, in which pyoverdine is 230 important for growth, we compared the growth of our wildtype strain PAO1 to the pyoverdine- Fig. S4 ). show an altered pyoverdine production response, but grew significantly better when exposed 310 to gallium (Fig. 3A-3D ). For the eight clones evolved under the flucytosine regime, changes 311 in the dose-response curves were both striking and uniform: growth and pyoverdine 312 production were no longer affected by the drug (Fig. 3E-3H UMP in the salvage pathway of pyrimidine (Fig. 5A) compromise RNA functionality more generally [73] . This sets the stage for selection to favor 
Conclusions and Implications
466
Our work advances research on anti-virulence drugs on multiple fronts. First, it shows that 467 resistant phenotypes are difficult to define, as they can involve the restoration of growth, the 468 resumption of virulence factor production, and/or the activation of a bypassing mechanism. 
